Literature DB >> 8328893

Prognostic value of triple phase bone scanning for reflex sympathetic dystrophy in hemiplegia.

L Weiss1, A Alfano, P Bardfeld, J Weiss, L W Friedmann.   

Abstract

Twenty-two patients with cerebral vascular accident (CVA), clinically confirmed by head computed tomography, were observed for symptoms of the reflex sympathetic dystrophy syndrome (RSDS). All patients received triple phase bone scans; 16 scans were positive for RSDS. Patients with negative scans had no symptoms of RSDS. Five patients with positive scans had RSDS symptoms at the time of bone scanning. Seven of 11 patients with positive scans but no symptoms of RSDS at the time of bone scan developed symptoms of RSDS within six months. We found a significant relationship between positive bone scans and the subsequent development of RSDS (p < 0.01). Considering only those patients who were asymptomatic for RSDS at the time of bone scanning, we found bone scanning to be a good predictor for the future development of clinical RSDS. We found the correlation between positive bone scans and the subsequent development of clinical RSDS in previously asymptomatic individuals to be statistically significant (p < 0.05). We conclude that bone scans may be a good predictor of patients at risk for developing clinical RSDS after CVA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8328893     DOI: 10.1016/0003-9993(93)90032-6

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  2 in total

1.  The predictive value of additional late blood pool imaging to the three-phase bone scan in the diagnosis of reflex sympathetic dystrophy in hemiplegic patients.

Authors:  Berna Okudan; Canan Celik; Seyfi Serttas; Neşe Ozgirgin
Journal:  Rheumatol Int       Date:  2005-01-15       Impact factor: 2.631

Review 2.  Usefulness of bone scintigraphy for the diagnosis of Complex Regional Pain Syndrome 1: A systematic review and Bayesian meta-analysis.

Authors:  Maria M Wertli; Florian Brunner; Johann Steurer; Ulrike Held
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.